


下載本文檔
版權(quán)說(shuō)明:本文檔由用戶(hù)提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、金屬硫蛋白過(guò)表達(dá)對(duì)乳腺癌化療方案選擇的影響 11-03-27 16:22:00 編輯:studa20 作者:董建峰 馬潔華 張輝 張曉麗 薄愛(ài)華【摘要】 目的:探討金屬硫蛋白(Metallothionein,MT)在
2、乳腺癌中過(guò)表達(dá)的意義及其與乳腺癌化療方案選擇的相關(guān)性。方法:利用SP免疫組織化學(xué)技術(shù),檢測(cè)88例乳腺癌組織中MT表達(dá)率。結(jié)果:MT在乳腺癌中總陽(yáng)性率為67.05%(59/88)。MT在髓樣癌、小葉癌和導(dǎo)管癌中的陽(yáng)性率分別為41.67%,85.71%和62.50%。在浸潤(rùn)型乳腺癌組陽(yáng)性率明顯高于非浸潤(rùn)型癌組(P<0.05);在小葉癌組陽(yáng)性率高于髓樣癌組和導(dǎo)管癌組(P<0.05);淋巴結(jié)轉(zhuǎn)移組陽(yáng)性率高于非轉(zhuǎn)移組(P<0.05)。結(jié)論:MT表達(dá)與乳腺癌的病理類(lèi)型及有否淋巴結(jié)轉(zhuǎn)移相關(guān),檢測(cè)MT對(duì)乳腺癌化療方案的制定有指導(dǎo)意義。 【關(guān)鍵詞】 金屬硫蛋白;乳腺腫瘤;免疫組織化
3、學(xué)Since the first report of metallothionein(MT)overexpression in thyroid cancer tissues by Cherian and Nartey in 19871,there has been an extensive interest in the role which is played by MT in tumorigenesis.The abnormal increase of MT is related to the genesis,development and drugresistance of tumor2
4、.To investigate the expression of MT in breast cancer and its clinical significance,we collected 88 cases with breast cancer to examine the expression of MT with streptavidin peroxidase(SP)immunohistochemical method,The aim was to clarify the relation between the expression of MT and the biology cha
5、racteristic of tumor cell,and offer a base of establishing chemistry treatment scheme.1 Materials and methods1.1 Patients and samples88 cases with breast cancer in women were collected from January 2005 to October 2008 at No.1 Affiliated Hospital Hebei North University in Zhangjiakou.The age range w
6、as 30 to 79 years old,the average age was 51.5 years,and the median age was 48.5 years.1.2 Immunohistochemical stainingMouse antimetallothionein antibody was conducted by Santa Cruz,USA.Immunohistochemical staining SP kit and DAB kit were purchased from Beijing Zhongshan Goldenbridge biotechnology C
7、o.Ltd.(China).The samples of cancer were fixed in 100mL/L dehydrated formaldehyde and embedded in paraffin,sections of 5m thickness were sliced,which were dyed by HE staining method,and all samples were confirmed by pathological diagnosis and clinical classitication.Immunohistochemical SP staining m
8、ethod was used in the experiment with conventional staining procedures.The negative control was designed as PBS instead of antibody I,the positive control was known as positive tissue sections which was provided by Beijing Zhongshan Co.Ltd.(China).1.3 Statistical analysis2 test was used for statisti
9、cal analysis,P value less than 0.05 was considered as statistical significance.2 ResultsThe MT immunoreactive productions was showed brown with yellow color and distributed in cytoplasm of the cancer cells.But the cell nucleus and negative control cell were showed no color(Fig13).The relationship be
10、tween the expression of MT and the biology characteristic of carcinomer cell was showed in Tables 1.Table 1 Relationship between MT expression and pathology type,lymph metastases in breast cancerGroupnBreast Cancer MT(+)n%Total positive rate885967.05Marrow cancer12541.67Lobular cancer282485.71Ductal
11、 carcinoma483062.50Infiltrating cancer 685276.47Noninfiltrating cancer20735.00Lymph metastases393076.92Nonlymph metastases492959.18:Positive rate was significantly higher than that of marrow cancer group and ductal carcinoma group(P<0.05);:Positive rate was significantly higher than that of nonin
12、filtrating cancer group(P<0.05);:Positive rate was significantly higher than that of Nonlymph metastases group(P<0.05)Fig 1 Infiltrating ductal carcinoma (SP,×400)Fig 2 Infiltrating lobular cancer (SP,×400)Fig 3 Marrow cancer (SP,×400) DiscussionThe MT is protein of small molecu
13、lar with much sulfydryl.MT gene is located at chromosome 16.MT proteins are small molecular weight proteins containing 61 to 68 amino acid residue,and are characterized by high cysteine content with a paucity of aromatic acids,there is 25%30% cysteine of in MT.In human,there are four subgroup of MT
14、proteins,namely MT1,MT2,MT3 and MT4,and each subgroup can be classified into and 3.Because MT exhibit the selective chelating power for heavy metal ion such as zine(Zn),copper(Cu),cadmium(Cd)and platinum(Pt),they are involved in heavy metal complex.MT has close relation to absorption,transportation and metabolism of many trace elements.MT has also been implicated in chemoresistance to anticancer drugs and in scavenging free radical in cells4.The clearance ability of MT is 38.5 times higher than that of glutathione according to the relevant report,e
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 公務(wù)往返簽證管理辦法
- 北京收容管理辦法修訂
- 創(chuàng)新重點(diǎn)稅源管理辦法
- 公益訴訟損害管理辦法
- 回收芯片高頻管理辦法
- 團(tuán)隊(duì)目標(biāo)考核管理辦法
- 醫(yī)療廢物出境管理辦法
- 作業(yè)工具管理辦法臺(tái)賬
- 林業(yè)園林建設(shè)管理辦法
- 接收機(jī)系統(tǒng)設(shè)計(jì)與仿真
- 初一生活學(xué)習(xí)指導(dǎo)
- 下肢靜脈曲張
- 2024年露營(yíng)帳篷項(xiàng)目可行性研究報(bào)告
- 《公務(wù)員錄用體檢操作手冊(cè)(試行)》
- 2024粵東西粵北地區(qū)教師全員輪訓(xùn)培訓(xùn)心得總結(jié)
- 2024-2025學(xué)年華東師大版數(shù)學(xué)七年級(jí)上冊(cè)計(jì)算題專(zhuān)項(xiàng)訓(xùn)練
- 福建省機(jī)關(guān)工作人員年度考核登記表
- JBT 7808-2010 無(wú)損檢測(cè)儀器 工業(yè)X射線探傷機(jī)主參數(shù)系列
- DB44-T 2474-2024 自然教育標(biāo)識(shí)設(shè)置指引
- 研學(xué)基地合作協(xié)議
- 駕駛員行為規(guī)范管理制度
評(píng)論
0/150
提交評(píng)論